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Acute myeloid leukemia (AML) is a heterogeneous group of diseases in terms of clinical presentation, genetic alterations and response to treatment. Cytogenetic abnormalities that are identified in B55% of all adult patients with AML enable subclassification and risk stratification. Fusion genes can be detected in B20-25% of all AML cases, and usually are the result of a cytogenetically detectable chromosomal rearrangement. Most recurrent chromosomal alterations are associated with specific morphological and clinical characteristics, 1 such as the reciprocal t(8;21)/RUNX1-RUNX1T1, inv(16)/CBFB-MYH11 and t(15;17)/ PML-RARA rearrangements, all of which are associated with good prognosis. In contrast, complex aberrations with X3 chromosomal abnormalities are associated with inferior outcome. 2 However, even in high-quality cytogenetic preparations, G-banding analysis suffers from an inherent limit in resolution, such that rearrangements o5-10 megabases in size, particularly those involving uniformly pale G-banded regions, may be impossible to be detected. Molecular genetic approaches such as reverse transcriptase-PCR (RT-PCR) have demonstrated that a small percentage of apparently normal karyotypes may harbor cryptic versions of known recurrent translocations, which are generated by submicroscopic insertions or more complex rearrangements. 3 The cryptic NUP98-NSD1 fusion involves the nucleoporin gene 98 (NUP98) on chromosome 11p15 and the non-homeobox gene NSD1 in chromosomal band 5q35. NUP98 encodes a 98-kDa protein of the nuclear pore complex, and is known to fuse to at least 21 different fusion gene partners in chromosomal rearrangements of various hematopoietic disorders.
4 NSD1 contains two distinct nuclear receptor interaction domains, as well as a SET domain and multiple PHD fingers, both of which are frequently found in transcriptional regulators and may be involved in chromatin remodeling. 5, 6 NSD1 is thought to function as both a transcriptional coactivator and a corepressor. The NUP98-NSD1 fusion gene has been shown to induce AML in vivo, which sustains self-renewal of myeloid stem cells in vitro, and enforces expression of the HOXA7, HOXA9, HOXA10 and MEIS1 proto-oncogenes. 7 Recently, Hollink et al. 8 published a study on NUP98-NSD1 in 293 pediatric and 808 adult cytogenetically normal AML (CN-AML) cases. The NUP98-NSD1 fusion gene has been described in this single study with a frequency of 16.1% in pediatric and 2.3% in adult AML patients with distinct characteristics (for example, mutual exclusiveness with NPM1) and dismal prognosis. The aim of our study was to further investigate the frequency and clinical relevance of the NUP98-NSD1 fusion transcript in 378 adult cases of de novo NPM1 unmutated (NPM1wt) CN-AML. Furthermore, we screened 64 adult AML cases with cytogenetic aberrations involving chromosomes 5 and 11 for the presence of NUP98-NSD1 fusion gene. In addition, we aimed at evaluating this fusion transcript as a target for quantitative RT-PCR (qRT-PCR)-based minimal residual disease (MRD) monitoring. The study design adhered to the tenets of the Declaration of Helsinki and was approved by our institutional review board before its initiation. NUP98-NSD1 fusion transcript analysis was performed on either bone marrow or peripheral blood samples. Presence of Letters to the Editor NUP98-NSD1 fusion transcript was determined by PCR and validated by direct Sanger sequencing using the following primers: NUP98ex12-F: 5 0 -GATTTAATACTACGACAGCCACTTT-3 0 and NSDex6-R: 5 0 -GGAACTTACCTTGTGCACC-3 0 . qRT-PCR was performed by the use of the LightCycler 1.5 System (Roche Diagnostics, Mannheim, Germany). Amplification was performed with the PCR primers described above. Detection probes were as follows: NUP98-NSD1-FL, 5
0 -AGCTGTGCGGTCAGAGAAGAA-Fluo-3 0 and NUP98-NSD1-FLC640, 5 0 -LCRed-640-GCCTTAGGAAGCCAAG-CAAGTGGC-Pho-3 0 . The expression of the fusion gene NUP98-NSD1 was normalized against the expression of the control gene ABL1 to adjust for the variations in mRNA quality and efficiencies of complementary DNA synthesis. The NUP98-NSD1 mutation levels are given as % NUP98-NSD1/ABL1. Quantification of ABL1 was performed as described previously. 9 To analyze the efficiency and sensitivity of NUP98-NSD1 specific assay, we performed serial dilution experiments of NUP98-NSD1-positive diagnostic samples in NUP98-NSD1-negative complementary DNA of individual patients. The mutation status of other genes was as follows: NPM1: n ¼ 378, FLT3-ITD: n ¼ 378, CEBPA: n ¼ 377, MLL-PTD: n ¼ 375, RUNX1: n ¼ 348, ASXL1: n ¼ 371, FLT3TKD: n ¼ 344, and WT1: n ¼ 366. Female/male ratio was 144/234, and age ranged from 15.7 to 89.6 years (median: 63.7) ( Table 1) . A NUP98-NSD1 fusion transcript was detected in 8/378 NPM1wt CN-AML cases (2.1%), indicating that it is a rare event in adult CN-AML. Patients with del(5q) or complex aberrations were all negative for NUP98-NSD1. In contrast, the single patient with ins(5;11) (q35;p13p15) harbored a NUP98-NSD1 fusion transcript. We observed significantly higher bone marrow blast counts in NUP98-NSD1-positive cases compared with negative cases (mean blast cells 73% vs 53%, P ¼ 0.039). Sex (4 males vs 4 females) and white blood cell count at diagnosis (median number of cells 80.4 vs 28.9; P ¼ 0.224) were not different compared with NUP98-NSD1-negative cases, as well as hemoglobin level (median level 8.7 vs 9.4; P ¼ 0.323) and platelet count (median number of cells 115.3 vs 94.4; P ¼ 0.584) ( Table 1) . With regard to cytomorphology, NUP98-NSD1-positive cases were restricted to AML M1 (n ¼ 5/100), AML M2 (n ¼ 2/155) and AML M4 (n ¼ 1/74) FAB subgroups (Supplementary Figure 1) . In 194 cases immunophenotyping data was available. Cases with the NUP98-NSD1 fusion transcript as compared with those without revealed a more immature phenotype with stronger expression of CD34 (mean number of positive cells: 73 ± 30% vs 41 ± 28%, Po0.001). Furthermore, a stronger expression of HLA-DR was observed (mean number of positive cells: 62 ± 18% vs 38±22%; P ¼ 0.058). CN-AML patients with NUP98-NSD1 fusion were younger than the NUP98-NSD1-negative patients (median: 42.3 vs 62.4 years, Po0.001) ( Table 1) . A distribution according to age decades is depicted in Figure 1a . The age range of NUP98-NSD1-positive cases was 20.9-71.4 years, indicating that NUP98-NSD1 translocation is not restricted to younger age, although it appears to be more frequent in those below 50 years of age. This age-dependent frequency resembles that of the core-binding factor AML (t(8;21)/RUNX1-RUNX1T1 and inv(16)/CBFB-MYH11), which also occurs more frequently in younger patients. Interestingly, other NUP fusion genes such as NUP98-HOXA9 and DEK-NUP214 have also been associated with a younger age.
10,11
NPM1wt and CN-AML NUP98-NSD1-positive cases had a significantly higher frequency of FLT3-ITD and WT1 mutations compared with NUP98-NSD1-negative cases (6/8, 70.0% vs 67/367, 18.1%; P ¼ 0.001; and 4/8, 50.0% vs 23/358, 6.4%; P ¼ 0.001, respectively). Furthermore, in NUP98-NSD1-positive cases no RUNX1, CEBPA and FLT3-TKD mutations were detectable, but because of the low number of NUP98-NSD1-positive patients, this mutual exclusiveness is not significant. (Table 1 ). The association of NUP98-NSD1 with the class I aberration FLT3-ITD has previously been shown by Hollink et al., 8 and recent studies have also found other NUP98 fusions to be associated with FLT3-ITD. 10, 12 These findings support the hypothesis of multistep AML pathogenesis that may require the cooperation of class I and class II mutations. This theory is supported by the fact that we did not find any coincidence of a NUP98-NSD1 fusion transcript with the class II mutations such as RUNX1 and CEBPA, which again has also been shown by Hollink et al., 8 and also for other NUP98 fusions. 10, 12 In addition, our mutation analysis showed that WT1 mutations were significantly associated with the presence of NUP98-NSD1 fusion transcript, implying a critical role of WT1 genetic alteration in cooperation with NUP98-NSD1 in the pathogenesis of this subtype of AML. Mutations of WT1, which normally induces cellular quiescence and differentiation, 13 occur in 10% of CN-AML patients and may be associated with drug resistance.
14 The strong association between NUP98-NSD1 and WT1 mutations has also been described by others, 8, 12 and suggests that these two genes could interact in acceleration of leukemogenesis and in conferring a poor response to chemotherapy. Interestingly, 4/8 NUP98-NSD1-positive patients harbored simultaneously FLT3-ITD and WT1 mutations, thus further emphasizing the assumed poor clinical outcome of NUP98-NSD1-positive AML. The NUP98-NSD1 fusion transcript did not show an impact on overall survival. However, event-free survival (EFS) of NUP98-NSD1-positive patients was significantly worse compared with patients negative for NUP98-NSD1 (median: 1.8 vs 11.0 months; P ¼ 0.045, Figure 1b) . This is in line with the study of Hollink et al., 8 who reported that 4-year EFS rates of NUP98-NSD1-positive cases were below 10% for the adult cases studied. 8 Furthermore, we show that NUP98-NSD1 is a suitable and specific target for MRD monitoring. The sensitivity of NUP98-NSD1-specific assay was 1:10 000 (Supplementary Figure 2) . Of the three NUP98-NSD1-positive patients, bone marrow samples were available at different time-points during the clinical course. All the three patients were either refractory to induction chemotherapy or relapsed within 2 years of diagnosis (Figure 1c) , thus emphasizing NUP98-NSD1 as a factor for dismal clinical outcome. In conclusion, we were able to show that the NUP98-NSD1 fusion transcript is a rare event in adult NPM1wt CN-AML. However, NUP98-NSD1-positive AML seems to be a distinct entity, as it is associated with younger age, CD34 overexpression and very poor EFS. Another prominent feature of NUP98-NSD1-positive cases is their significantly higher blast counts. The NUP98-NSD1 fusion transcript has been shown to correlate with FLT3-ITD, which is associated with increased blast percentages. 15 Our data indicate that NUP98-NSD1 may function as an enhancer of the proliferative effect of FLT3-ITD. To our knowledge, this is the first report of a correlation of a NUP98 fusion with higher blast counts. Furthermore, NUP98-NSD1 seems to be a suitable marker for sensitive PCR-based monitoring of MRD. Thus, our data suggest performing PCR-based screening for NUP98-NSD1 in CN-AML cases that lack NPM1, CEBPA and RUNX1 mutations to identify this subgroup of poor-risk AML patients. Hypodiploidy (o46 chromosomes) is found in B5-8% of acute lymphoblastic leukemia (ALL). 1,2 It may be subdivided into high hypodiploidy (40-45 chromosomes), low hypodiploidy (HoL; 33-39 chromosomes) and near haploidy (23-29 chromosomes) with distinct genetic and clinical features. 2, 3 Only single cases with 30-32 chromosomes have been reported in the literature and it is therefore not known how such ALL should be classified. 4 The majority of patients with hypodiploid ALL have 45 chromosomes; near haploidy and HoL are very rare, comprising o1% of B-cell precursor (BCP) ALL. 2, 4 Near-haploid ALL is seen primarily in children and adolescents, although some adult cases have been reported, whereas HoL occurs at all ages. 4 Cases usually have an early pre-B immunophenotype and a white blood cell count of o50 Â 10 9 /l; the sex ratio is close to 1. 2, 5, 6 In childhood ALL, both near haploidy and HoL are associated with a dismal prognosis, with a 3-year event-free survival rate of 30%; adult patients with HoL also have extremely poor overall survival rates of only 20-30%. 2, 3, 7, 8 Because of the rarity of near-haploid/HoL ALL, relatively few studies have focused on these genetic subgroups and no single nucleotide polymorphism (SNP) array data have been reported to date. Considering the poor prognosis of these cases, further investigations are needed to increase our understanding of the pathogenetic impact of massive chromosomal loss in ALL. In the present study, we performed SNP array analyses of near-haploid and HoL ALL to characterize the chromosomal pattern, identify submicroscopic genetic aberrations, and investigate the mechanism of formation. The study comprised a total of 12 cases of near-haploid (n ¼ 8) and HoL (n ¼ 4) BCP ALL (Table 1) obtained via an international collaboration between four laboratories in Sweden and the United Kingdom; because of the rarity of these cases, a population-based study could not be performed. Diagnostic DNA and in cases 4 and 6 DNA from relapse was extracted according to standard methods from bone marrow and SNP array analysis was performed using the Illumina HumanOmni1-Quad BeadChip platform, containing B1.1 million markers (Illumina, San Diego, CA, USA), according to the manufacturer's instructions; data analysis was performed using the Genome studio v2011.1 software.
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All 12 cases displayed loss of heterozygosity (LOH) resulting from monosomies or uniparental isodisomies (UPIDs) for the majority of the chromosomes ( Supplementary Figures 1 and 2) . Chromosome 21 was retained in two copies (heterodisomy) in all near-haploid cases, followed by retention of both copies of chromosomes 14 (6/8; 75%), X/Y (5/8; 63%), 18 (3/8 cases each; 38%), and 8 and 10 (2/8 each; 25%) (Table 1 ), in line with previous studies. 1, 2, 5 The HoL cases displayed retention of both copies of chromosomes 1, 5, 6, 10, 11, 18, 19, 21 , and 22 (4/4 cases each; 100%), X/Y, 8, and 14 (3/4 each; 75%) (Table 1) , also agreeing well with previous investigations. 2, 6 Thus, both the near-haploid and the HoL cases displayed a non-random retention of both parental copies of chromosomes X/Y, 14, 18 and 21. The reason why some chromosomes are preferentially heterodisomic is unknown. Other tumor types with similar modal numbers also harbor specific heterodisomies; however, the involved chromosomes vary. For example, heterodisomies 18 and 21 are seen also in near-haploid/HoL hematologic malignancies other than ALL, whereas heterodisomies 5, 7, 19 and 21 are common in hyperhaploid chondrosarcomas. 9, 10 Chromosome 21, on the other hand, has been found to be retained in two copies in the vast majority of hypodiploid neoplasms. 9 The pathogenetic consequences of near haploidy and HoL, that is, why some chromosomes display retained heterozygosity whereas others are monosomic, remain unclear, but it is likely that the loss of chromosomes will affect gene expression. For example, genes that are expressed in a monoallelic manner, either because of random inactivation or imprinting, may be affected. Furthermore, haploinsufficiency of some of the genes on the monosomic chromosomes may also contribute.
In both near-haploid and HoL ALL, a clone constituting a duplication of the stemline, with two and four copies of chromosomes in the doubled clone corresponding to one and two copies in the original near-haploid/HoL clone, is frequently seen. 2, 6 All cases in the present study harbored complete LOH for chromosomes that were not retained. This could correspond either to the majority of chromosomes being monosomies or to all disomic chromosomes being UPIDs in a duplicated clone. In the SNP array analysis, probes were normalized against the mean copy number and it was therefore not possible to determine whether the analysis targeted the stemline or the duplicated clone in most cases. However, by cytogenetic analysis, the majority harbored a clone with 50-74 chromosomes (Table 1) , making it likely that the SNP array results correspond to the duplicated clone, although we cannot exclude that the culturing of cells for banding analysis affected the sizes of the different clones. Taken together, our findings agree well with the handful of previously reported cases in that the vast majority of gained chromosomes were 2:2 tetrasomies and the remaining chromosomes were UPIDs in the duplicated clone.
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The doubled clone in near-haploid and HoL cases may be mistaken for a high hyperdiploid ALL; a separate genetic subgroup with 51-67 chromosomes associated with a favorable outcome in both childhood and adult ALL. Thus, careful examination is important at diagnosis to prevent erroneous classification. 12 In fact, two of the cases in this study (no. 4 and 6) were initially classified and treated as high hyperdiploid ALL, that is, as nonhigh risk ALL, since only the duplicated clone was detected by cytogenetic analysis at the time of diagnosis. Both of these patients suffered a relapse, stressing the importance of correct treatment stratification. Notably, the underlying near haploidy was immediately identified when these cases were investigated with SNP array analysis. Although duplicated near-haploid/HoL clones may be recognized as such by all gained chromosomes being Accepted article preview online 14 August 2012; advance online publication, 2 October 2012
